A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

BACKGROUND: The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. Chime...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tongjuan, Zhang, Yuanyuan, Peng, Dan, Mao, Xia, Zhou, Xiaoxi, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383265/
https://www.ncbi.nlm.nih.gov/pubmed/30791947
http://dx.doi.org/10.1186/s40425-019-0529-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383265/
https://www.ncbi.nlm.nih.gov/pubmed/30791947
http://dx.doi.org/10.1186/s40425-019-0529-9

Ejemplares similares